This review highlights the efficacy, safety, and pleiotropic benefits of candesartan in managing high-risk hypertension with comorbidities.
Answers are grounded in this paper and cite their sources.
May support candesartan in high-risk hypertension with comorbidities; leaves open need for confirmatory RCTs.
This paper presents an overview of the literature on the treatment of arterial hypertension drugs that block the renin-angiotensin-aldosterone system (RAAS) – angiotensin receptor blockers ΙΙ (ARB), whose action is based on inhibition of the RAAS at the AII receptor. ARB candesartan (atakand), along with a strong long-term antihypertensive effect has organoprotective (causes regression of LVH has nephroprotection) antidiabetogennym effect, prevents the development of stroke. Clinical experience suggests candesartan, high efficiency and a good range of security among different categories of hypertensive patients with concomitant pathology, chronic heart failure, diabetes, obesity.
No takes yet. Share an insight, caveat, or question.
Т. Е. Морозова (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: